No photo of Shuo Ma

View Scopus Profile

Shuo Ma

  • 2375 Citations
19992020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Dr. Ma' clinical and research interests are focused on chronic lymphoid malignancies,including chronic lymphocytic leukemia and non-Hodgkin lymphoma. Dr. Ma directs the clinical and translational research initiatives in chronic lymphocytic leukemia (CLL) to develop and study novel treatment agents for the treatment of CLL. Her translational investigations have included novel biologic agents, mechanisms of drug resistance and immunotherapy. Dr. Ma is the Principal Investigator for a number of investigator-initiated and industry-sponsored clinical trials studying new exciting treatments agents for CLL and lymphoma. She collaborates with investigators at Northwestern University, other US institutions and international institutions in developing novel therapeutic approaches in hematologic malignancies.

Certifications and Licenses

Medical Oncology
Hematology
Internal Medicine

Training Experience

2005Residency, Resurrection Hospitals
2008Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)

Education/Academic qualification

PhD, Northwestern University Feinberg School of Medicine

… → 2000

MD, Beijing Medical University

… → 1994

Research interests

  • Biologic Therapies
  • Blood Cancer (leukemia and lymphomas)
  • Chronic Lymphocytic Leukemia
  • Hematology
  • Non-Hodgkin's Lymphoma
  • Oncology

Fingerprint Dive into the research topics where Shuo Ma is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Prot #ACE-LY-003: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

Ma, S.

Syneos Health, Inc., Acerta Pharma, LLC

8/21/19 → 8/21/22

Project: Research project

Prot #U2-VEN-109: Phase I/II Study of Venetoclax in Combination with Ublituximab and Umbralisib (TGR-1202) in Patients with Relapsed or Refractory CLL/SLL

Ma, S.

TG Therapeutics, Inc.

4/12/19 → 4/12/24

Project: Research project

Prot #BGB-3111-212: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma

Ma, S.

PRA Health Sciences, BeiGene Ltd.

2/8/19 → 2/8/22

Project: Research project

Prot #BGB-3111-304: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Ma, S.

PRA Health Sciences, BeiGene Ltd.

2/5/19 → 2/5/22

Project: Research project

Prot #017004: An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Ma, S.

DrugDev Inc., Juno Therapeutics, Inc.

1/18/19 → 1/18/22

Project: Research project

Research Output

Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies

Stasiłojć, G., Felberg, A., Urban, A., Kowalska, D., Ma, S., Blom, A. M., Lundin, J., Österborg, A. & Okrój, M., Jan 2020, In : Journal of Immunological Methods. 476, 112675.

Research output: Contribution to journal › Article

Open Access
    • 1 Scopus citations

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology

    Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Lim, M. S., Ma, S. & 10 others, Malek, S., Mato, A., Mosse, C., Shadman, M., Siddiqi, T., Stephens, D., Sundaram, S., Wagner, N., Dwyer, M. & Sundar, H., Feb 1 2020, In : Journal of the National Comprehensive Cancer Network : JNCCN. 18, 2, p. 185-217 33 p.

    Research output: Contribution to journal › Article

    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

    Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Ma, S., Malek, S. & 9 others, Mato, A., Mosse, C., Neppalli, V. T., Shadman, M., Siddiqi, T., Stephens, D., Wagner, N., Dwyer, M. A. & Sundar, H., Jan 2019, In : JNCCN Journal of the National Comprehensive Cancer Network. 17, 1, p. 12-20 9 p.

    Research output: Contribution to journal › Article

    • 11 Scopus citations

    Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

    Roberts, A. W., Ma, S., Kipps, T. J., Coutre, S. E., Davids, M. S., Eichhorst, B., Hallek, M., Byrd, J. C., Humphrey, K., Zhou, L., Chyla, B., Nielsen, J., Potluri, J., Kim, S. Y., Verdugo, M., Stilgenbauer, S., Wierda, W. G. & Seymour, J. F., Jul 11 2019, In : Blood. 134, 2, p. 111-122 12 p.

    Research output: Contribution to journal › Article

    • 15 Scopus citations

    Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia

    Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Ervin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., Ma, S., Tausch, E., Cramer, P., Huang, J. & 4 others, Mitra, S., Hallek, M., O’Brien, S. M. & Stilgenbauer, S., Jan 1 2019, In : Journal of Clinical Oncology. 37, 16, p. 1391-1402 12 p.

    Research output: Contribution to journal › Article

    Open Access
    • 26 Scopus citations